A Phase 1, Open Label, Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MG1102 in Patients with Solid Tumors.

Trial Profile

A Phase 1, Open Label, Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MG1102 in Patients with Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs MG 1102 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 28 Mar 2017 Status changed from discontinued to completed, according to the results published in the Investigational New Drugs
    • 28 Mar 2017 Results published in the Investigational New Drugs
    • 25 Nov 2015 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top